| Targeted Signal Modulation in Renal Cell Carcinoma and Prostate Cancer |
|
- Targeting the VEGFR Axis in RCC
- Small-Molecule VEGFR Inhibitors: Integrating Multiple Lines of Therapy for Recurrent RCC
- Risk Prognostication and Tumorigenesis in Prostate Cancer
- Prevention and Early Intervention in Prostate Cancer
1 AMA PRA Category 1 Credit™
Expiration date: May 14, 2009 |
| Practical Updates in Renal Cell Carcinoma |
|
- Utilizing Prognosis Assessment for Treatment Strategy Development in Metastatic Renal Cell Carcinoma
- Case 1: A 65-year-old male
- Case 2: A 48-year-old female
- Case 3: A 64-year-old female
1 AMA PRA Category 1 Credit™
Expiration date: March 3, 2009 |
| Cancer Conference Highlights Vol. 9, No. 9 |
|
- Current and Future Therapeutic Options for
Patients With Advanced Hormone-Refractory Prostate Cancer
- Novel Oral Platinum Analogues in the Treatment of Patients
With Hormone-Refractory Prostate Cancer
- Satraplatin in Hormone-Refractory Prostate Cancer
- Molecular-Targeted Agents in Advanced Prostate Cancer
- Targeting Epigenetics in Prostate Cancer
1 AMA PRA Category 1 Credit™
Expiration date: November 30, 2008 |
| Current Perspectives on Targeted Therapies for Advanced Renal Cell Carcinoma |
|
- Neoadjuvant Targeted Therapy Approaches in Advanced RCC
- Targeted Therapies as Standard of Care in mRCC
- Are Multitargeted TKIs the Standard of Care in Patients With Previously Treated mRCC?
- Sequential Targeted Therapy in RCC
1 AMA PRA Category 1 Credit™
Expiration date: November 30, 2008 |
| The Interface Between Molecular Biology and Clinical Practice: Targeting the Ras/Raf Signaling Network in Cancer |
|
- Efficacy of Biologic Targeted Agents in Hepatocellular Carcinoma
- Antiangiogenic Agents in NSCLC
- Beyond Proof of Principle for Multikinase Inhibitors in Renal Cell Carcinoma
- Update on Therapeutic Inhibition of Raf in Metastatic Melanoma
1 AMA PRA Category 1 Credit™
Expiration date: October 31, 2008 |
| Case Studies in Oncology Vol. 8, No. 6 |
|
- Bevacizumab/Interferon Alfa in Metastatic RCC
1 AMA PRA Category 1 Credit™
Expiration date: September 30, 2008 |
| Cancer Abstracts & Summaries Vol. 8, No. 4 |
|
- New Targeted Agents and Combinations in RCC
- First-line Interferon Alfa-2a/Bevacizumab in mRCC
- Sunitinib/Bevacizumab in mRCC Temsirolimus or Interferon Alfa in Advanced RCC
- Temsirolimus/Bevacizumab in Advanced RCC
- Axitinib in Sorafenib-Refractory mRCC
- Pazopanib in Metastatic Clear Cell RCC
- mTOR Inhibition by Everolimus in RCC
1 AMA PRA Category 1 Credit™
Expiration date: August 31, 2008 |
| Cancer Abstracts & Summaries Vol. 8, No. 3 |
|
- Targeted Therapies in Hepatocellular and Renal Cell Carcinomas
- Phase III SHARP Trial: Sorafenib in Advanced Hepatocellular Carcinoma
- Sunitinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety<
- Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program in North America: Initial Results
- Survival and Biomarker Analysis of Sorafenib in Advanced RCC
- Sunitinib Compared to Interferon Alfa in Metastatic RCC
1 AMA PRA Category 1 Credit™
Expiration date: August 31, 2008 |
| Oncology Briefings Vol. 5, No. 3 |
|
- First-line Chemotherapy/Targeted Agents in Advanced Pancreatic Cancer
0.5 AMA PRA Category 1 Credit™
Expiration date: August 31, 2008 |
| Monographs in Renal Cell Carcinoma Vol. 2, No. 1 |
|
- Mechanisms of Action for Targeted Agents in RCC
- Multitargeted Kinase Inhibitors in Pretreated RCC
- Antiangiogenic Treatment Strategies in RCC
1 AMA PRA Category 1 Credit™
Expiration date: July 31, 2008 |
